N-(tert-Butylsulfonyl)-N'-methylharnstoff | 70282-61-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: N-(tert-Butylsulfonyl)-N'-methylharnstoff
• 英文别名: 1-Tert-butylsulfonyl-3-methylurea
• CAS: 70282-61-0
• 化学式: C₆H₁₄N₂O₃S
• 分子量: 194.255
• InChiKey: RKCHRXOGFBEMQK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-羟基-3-甲基脲 、 叔丁基磺酰氯 在 吡啶 作用下， 以 丙酮 为溶剂， 生成 N-(tert-Butylsulfonyl)-N'-methylharnstoff
  参考文献：
  名称：

  Bleeker,I.P.; Engberts,J.B.F.N., Recueil des Travaux Chimiques des Pays-Bas, 1979, vol. 98, p. 120 - 124

  摘要：

  DOI：

文献信息

• Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20170333399A1

  公开（公告）日：2017-11-23

  The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR and methods for their preparation and use.
• BIARYLMETHYL HETEROCYCLES
  申请人：Universite de Montreal

  公开号：US20190202808A1

  公开（公告）日：2019-07-04

  The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.